otherwise specified, angioimmunoblastic T-cell lymphoma, and sALCL (ALK1-negative). The most common treatment-related toxicities were nausea, vomiting, diarrhea, infection, asthenia, thrombocytopenia, and neutropenia. Cardiac toxicity was minimal (6
Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary A. Dwyer and Maoko Naganuma
neutropenia (70%), thrombocytopenia (45%), anemia (18%), and febrile neutropenia (15%). 17 Lenalidomide was administered using different dosing schedules in these earlier studies. In one study, patients initially received lenalidomide at the 25-mg-daily dose
Stephen Harnicar
monitor for and manage toxicities associated with imatinib. A CBC count should be performed weekly for the first month, every 2 weeks for the second month, and periodically thereafter (e.g., every 2-3 months). Hematologic toxicities, including neutropenia
Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Neel Gupta, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Oxana V. Makarova-Rusher, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank Palella, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Mary A. Dwyer and Deborah A. Freedman-Cass
itself (eg, hypogammaglobulinemia in chronic lymphocytic leukemia or multiple myeloma). 54 – 58 In particular, chemotherapy can cause neutropenia, a major risk factor for the development of infections. 59 The frequency and severity of infection are
Armin Rashidi and Nancy L. Bartlett
20 months, and the median PFS for all patients was 5.6 months (21.7 months for those who achieved a CR). The most common adverse event was peripheral sensory neuropathy (42%) and the most common grade 3 to 4 adverse event was neutropenia (20%). In
Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar and Leonard B. Saltz
) The most common grade 1/2 toxicities with FOLFOX were fatigue (58%), nausea (32%), and neutropenia (25%). The most common grade 3 toxicities were diarrhea (4%), fatigue (1%), nausea (1%), and neutropenia (1%). These were managed with dose reductions
Saurabh Rajguru and Brad S. Kahl
PFS was just 4 months, but the median response duration was 16.6 months, suggesting substantial clinical benefit in patients responding to treatment. The most common grade 3/4 AEs were neutropenia (43%) and thrombocytopenia (27%), with 34% and 31% of
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead and Rashmi Kumar
letrozole alone group included neutropenia (54% vs 1%) and leukopenia (19% vs 0%). Based on this study, the FDA approved palbociclib in combination with letrozole for the treatment of postmenopausal women with ER-positive, HER2-negative advanced breast
Ranjana H. Advani
associated with a 5% improvement in modified PFS but also higher rates of febrile neutropenia and neuropathy. The FDA indication approval recommends growth factor support with BV‐AVD. 8 The other issue to consider with these regimens is cost. Because of the
Melinda Telli
treated with docetaxel had significantly higher rates of febrile neutropenia and neuropathy, whereas in patients treated with carboplatin, vomiting appeared to be somewhat more common,” explained Dr. Telli. Furthermore, she said, “disappointingly, there
